Navigation Links
GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America

CHICAGO, March 9, 2011 /PRNewswire/ -- GlobalCare Clinical Trials, Ltd, (GlobalCare) today announced its expansion into Latin America. GlobalCare provides selected clinical study visits at convenient locations – such as in the home or alternate settings – for study patients to support phase I-IV trials in a variety of therapeutic areas, genomics and personalized medicine in all age groups. GlobalCare's patient-centric service model provides faster patient recruitment, better protocol compliance and higher retention rates, while helping to decrease the cycle of time to biopharmaceutical development and speed delivery of life-enhancing products to market for the benefit of patients worldwide.

Regulatory-compliant services provided by GlobalCare include: global project management; study drug administration; blood and other biologic sample collection; clinical assessments; patient training and education; device management; source documentation; and data collection. In addition, the company offers central and local out-patient pharmacy services including storage and distribution, compounding and dispensing, cold chain logistics, and sourcing of commercial products and devices.

Serving the Globe

GlobalCare provides services in over 20 countries and maintains a centrally managed network of multilingual country coordinators who are trained and certified on Good Clinical Practice/International Conference on Harmonization (GCP/ICH) guidelines and have in-depth knowledge of local medical practices and country cultural attitudes. The network is augmented by an extensive pool of over 20,000 qualified local traveling physicians and nurses in the United States, Canada, Australia, Europe, Israel, and now Latin America. GlobalCare's model enables patients to participate in clinical trials regardless of study duration; frequency of visits; disease state; distance to site; and/or family, work or community commitments by conducting study visits in a location convenient to them.

"GlobalCare continues to expand its network based on client demands, and Latin America has become one of the most prominent new clinical trials locations. The standard of medical training in Latin America is high and, due to improvements in the countries' regulatory legislation, investigators are knowledgeable in GCP/ICH guidelines. There are also large numbers of drug-naive subjects. Thus, it made sense to extend GlobalCare's services to this region, cost-effectively delivering high quality and flexible clinical trial services to patients in convenient settings like their home or office," said Gail Adinamis, founder and Chief Executive Officer of GlobalCare.

Reduction in subject recruitment time by over 50% and an increase in subject retention rate of over 95% are among the results that have spurred GlobalCare's rapid growth.

"As industry demand increases for accelerated patient enrollment and streamlined study processes on a global basis, we will continue to expand our network to facilitate the timely and successful completion of clinical trials across biopharmaceuticals while providing important return on investment for sponsors," Adinamis continued.

Therapeutic areas that tend to benefit the most from this model include, but are not limited to, oncology, neurology, infectious disease and the central nervous system. GlobalCare's services are also advantageous for the support of orphan drug studies, where patients typically live significant distances from investigative sites. And, GlobalCare employs an extensive screening and qualification process for its network members and maintains a rigorous quality management system to promote standardization globally while complying with all applicable regulations.

"In addition to our teamwork, quality and responsiveness, GlobalCare works with an unwavering commitment to patient care, safety and ethics," states Adinamis.

Leadership and Experience

With more than 100 years of collective experience in the clinical trials and home healthcare industries, the GlobalCare team has supported more than 350 trials, including several studies leading to commercialization of blockbuster products. With three decades of comprehensive phase I-IV clinical trials leadership, CEO Adinamis is also the founder and pioneer of the in-home and alternate site clinical trials model, which she introduced in 1992. Adinamis also spent 12 years in global clinical trials management at Abbott Laboratories and Astellas Pharma and established and led clinical trials divisions for three national home infusion companies as well as her former company, Clinical Resource Network, Inc.

Adinamis is joined by Janusz Kabata, MD, PhD, MBA, who serves as Chief Medical Officer and Director of European Operations for GlobalCare. Kabata brings over 30 years of medical experience to the company as an academic researcher and Medical Director in private healthcare institutions. He also provided two decades of work in successful coordination and management of international clinical trials.  

About GlobalCare Clinical Trials, Ltd

GlobalCare Clinical Trials, Ltd is a global niche service provider to government agencies and the world's biotechnology, pharmaceutical and medical device companies engaged in all phases of product development. GlobalCare offers an innovative patient-centric service model that provides selected clinical study visits in the home or alternate setting resulting in faster patient recruitment, better compliance and higher retention rates, helping to expedite time-to-market for life-enhancing products. Services are provided in over 20 countries, through an extensive network of multilingual Country Coordinators and over 20,000 local highly skilled ambulant clinicians in compliance with local and national regulations. Services include Global Project Management, local and central pharmacy services, study drug administration, blood and other biologic sample collection, clinical assessments, patient training and education, device management, source documentation, and data collection. For more information, please visit

SOURCE GlobalCare Clinical Trials, Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
3. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
4. Association of Clinical Research Organizations (ACRO) Welcomes Clinilabs and RPS as New Members
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
7. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
8. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
9. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
10. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
11. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
Post Your Comments:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... in Vilnius, Lithuania, announced today that they have entered into a multiyear collaboration ... to provide CRISPR researchers with additional tools for gene editing across all applications. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, ... in analytical testing are being attributed to new regulatory requirements for all new ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The ... transformative for performing systematic gain-of-function studies. , This complement to loss-of-function studies, ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... will be hosting a Webinar titled, “Pathology is going digital. Is your lab ... digital pathology adoption best practices and how Proscia improves lab economics and realizes ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):